GILEAD | Medical Information

Yeztugo® (lenacapavir) Injection Solution Storage and Stability

This document is in response to your request for information regarding Yeztugo® (lenacapavir [LEN]) 463.5 mg/1.5 mL (309 mg/mL) injection solution and extended storage and stability information.

This document does not intend to offer an opinion regarding the clinical relevance of these data or the advisability of storing or administering any drug in a manner inconsistent with its approved labeling. LEN should be stored according to the product label.

Some data may be outside of the US FDA-approved prescribing information. In providing this data, Gilead Sciences, Inc. is not making any representation as to its clinical relevance or to the use of any Gilead product(s). For information about the approved conditions of use of any Gilead drug product, please consult the FDA-approved prescribing information.

The full indication, important safety information, and boxed warning are available at: www.gilead.com/-/media/files/pdfs/medicines/hiv/yeztugo/yeztugo_pi.

Product Labeling[1]

Storage and Handling

Store at 20°C to 25°C (68°F–77°F), excursions permitted to 15°C to 30°C (59°F–86°F).

Keep the vials in the original carton until just prior to preparation of the injections in order to protect from light.

Once the solution has been drawn into the syringes, the injections should be administered as soon as possible.

Discard any unused portion of the solution.

Formulation Description

LEN injection is packaged in a dosing kit containing:

- 2 single-dose clear glass vials, each containing sufficient volume to allow withdrawal of 463.5 mg/1.5 mL (309 mg/mL) of lenacapavir. The injection solution is sterile, preservative-free, clear, and yellow with no visible particles. Vials are sealed with a stopper and aluminium overseal with flip-off cap.
- 2 disposable syringes, 2 withdrawal needles (18-gauge, 1½ inch), and 2 injection safety needles for subcutaneous injection (22-gauge, ½ inch).

The vial stoppers are not made with natural rubber latex.

Additional Storage and Handling Recommendations[2]

Storage and Handling

Refer to Product Labeling section for storage and handling. Do not use vials beyond expiration date.

In-Use

After the vial is removed from the original carton, the solution should be administrated as soon as possible. If the solution is not used within 4 hours, discard the solution.

Photosensitivity

LEN injection, 309 mg/mL, is photosensitive. Minimize exposure to light before and after preparation for use.

Alternative Storage and Stability Information[2]

The table below summarizes available data from in-house temperature excursion studies regarding the storage of LEN injection solution in varying conditions.

There is no change to the product expiration date if it has been stored for less than the acceptable duration specified for each temperature in Table 1. The "acceptable duration" refers to the stability of LEN injection solution in the specified packaging and storage condition, but it does not endorse alternative packaging or use beyond the expiration date stated on the original packaging.

Table 1. Summary of Extended Stability Data for LEN injection Solution[2]

Storage Condition	Package Type	Acceptable Duration
-20°C (-4°F)[a]	Original vial[b]	1 month
50°C (122°F)[a]	Original vial[b]	2 weeks
5°C (41°F)[a]	Original vial[b]	12 months
In-use photostability (exposure to ultraviolet/visible light)	In original vial or in syringe	4 hours total

[a] No exposure to light.
[b] Original vial removed from dosing kit.

References

1. Enclosed, Gilead Sciences Inc. YEZTUGO® (lenacapavir) tablets, for oral use. YEZTUGO® (lenacapavir) injection, for subcutaneous use. U.S. Prescribing Information. Foster City, CA.
2. Gilead Sciences Inc. Data on File.

Product Label

For the full indication, important safety information, and boxed warning, please refer to the Yeztugo US Prescribing Information available at: www.gilead.com/-/media/files/pdfs/medicines/hiv/yeztugo/yeztugo_pi.

Follow-Up

For any additional questions, please contact Gilead Medical Information at:

☎1-866-MEDI-GSI (1-866-633-4474) or 🖱 www.askgileadmedical.com

Adverse Event Reporting

Please report all adverse events to:

Gilead Global Patient Safety ☎ 1-800-445-3235, option 3 or
🖱 www.gilead.com/utility/contact/report-an-adverse-event

FDA MedWatch Program by ☎ 1-800-FDA-1088 or ✉MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or 🖱 www.accessdata.fda.gov/scripts/medwatch

Data Privacy

The Medical Information service at Gilead Sciences may collect, store and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead's affiliates, business partners, service providers and regulatory authorities located in countries besides your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement (www.gilead.com/privacy-statements) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact privacy@gilead.com.